Iqvia (NYSE:IQV) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday, February 20th.
According to Zacks, “IQVIA Holdings Inc. is a provider of information, innovative technology solutions and contract research services focused on using data and science which offer healthcare clients find better solutions for their patients. IQVIA Holdings Inc., formerly known as Quintiles IMS Holdings, Inc., is based in DURHAM, United States. “
IQV has been the subject of a number of other research reports. Royal Bank of Canada set a $118.00 price target on Iqvia and gave the stock a “buy” rating in a report on Thursday, February 15th. Piper Jaffray Companies restated a “hold” rating and issued a $103.00 price target on shares of Iqvia in a research report on Thursday, February 15th. JPMorgan Chase & Co. increased their price objective on Iqvia from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Mizuho set a $97.00 price objective on Iqvia and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, SunTrust Banks restated a “hold” rating and set a $110.00 price target on shares of Iqvia in a research report on Monday, January 22nd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $110.02.
Iqvia (IQV) traded down $0.84 on Tuesday, hitting $104.84. The stock had a trading volume of 1,111,427 shares, compared to its average volume of 1,186,370. Iqvia has a 52-week low of $76.80 and a 52-week high of $110.67. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 1.21. The company has a market cap of $22,062.05, a price-to-earnings ratio of 17.33, a price-to-earnings-growth ratio of 2.71 and a beta of 0.64.
Iqvia (NYSE:IQV) last announced its earnings results on Wednesday, February 14th. The medical research company reported $1.32 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.34 by ($0.02). The business had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. The firm’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the firm earned $1.09 earnings per share. research analysts forecast that Iqvia will post 2.84 earnings per share for the current fiscal year.
In related news, Director Michael J. Evanisko sold 816 shares of Iqvia stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $100.00, for a total transaction of $81,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider James H. Erlinger III sold 10,000 shares of Iqvia stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $99.97, for a total value of $999,700.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,816 shares of company stock valued at $3,093,400. Insiders own 6.00% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Franklin Street Advisors Inc. NC purchased a new stake in shares of Iqvia during the 4th quarter valued at $7,446,000. Chevy Chase Trust Holdings Inc. purchased a new stake in shares of Iqvia during the 4th quarter valued at $14,462,000. BlackRock Inc. purchased a new stake in shares of Iqvia during the 4th quarter valued at $942,532,000. Icon Advisers Inc. Co. purchased a new stake in Iqvia during the 4th quarter worth $852,000. Finally, Nisa Investment Advisors LLC purchased a new stake in Iqvia during the 4th quarter worth $920,000. Institutional investors own 92.34% of the company’s stock.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.